Safety and Efficacy of Extended-Release Niacin for the Treatment of Dyslipidaemia in Patients with HIV Infection: Aids Clinical Trials Group Study A5148

Meixner, Linda; Hoffman, Julie; Zwickl, Beth; Goldman, Mitch; Whitely, Kim; Conrad, Ann; J. Fichtenbaum, Carl; Hyc, Fran; Spitz, Teresa; Demarco Shaw, Debra; Norris, Jane; Stoudt, Sylvia; G. Castro, José; F Colon, L; Cavert, Winston; A. Fox, Kathy; P. Dubé, Michael; Wu, Julia; A. Aberg, Judith; A. Deeg, Mark; Alston‐Smith, Beverly; E. McGovern, Mark; Lee, Daniel; Shriver, S.; I. Martínez, Ana; Greenwald, Martha; H. Stein, James

doi:10.1177/135965350601100802

Public

Safety and Efficacy of Extended-Release Niacin for the Treatment of Dyslipidaemia in Patients with HIV Infection: Aids Clinical Trials Group Study A5148

Shared by NobleBlocks on Nov 1, 2006 • 12:00 AM UTC

Authors:

Linda Meixner

Julie Hoffman

Beth Zwickl

Abstract

ERN in doses up to 2,000 mg daily was safe, well-tolerated and efficacious in HIV-infected subjects with atherogenic dyslipidaemia. Increases in glycaemia and insulin resistance tended to be transient.

Subject

Internal medicine

Insulin resistance

Niacin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!